TAT-utrophin as a protein therapy for dystrophinopathies

Details TAT-utrophin as a protein therapy for dystrophinopathies TAT-utrophin as a protein therapy for dystrophinopathies

2011-01-04

2011-01-04

Ulm, John D (Department: 1649)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C514S002600, C530S350000, C536S023400

Reexamination Certificate

active

07863017

ABSTRACT:
Disclosed is a fusion protein including a full-length TAT-utrophin or an anti-dystrophinopathic fragment thereof, a method of treating dystrophinopathies (including Duchenne muscular dystrophy) using the fusion protein, a pharmaceutical composition for treating dystrophinopathies in mammals comprising the fusion protein, and nucleic acid constructs for expressing the fusion protein.

REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 2002/0192710 (2002-12-01), Kaufman
patent: 2005/0069985 (2005-03-01), Kaufman
patent: 2005/0158281 (2005-07-01), Chamberlain et al.
patent: 2006/0073586 (2006-04-01), Xiao
Schwarze et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Sep. 3, 1999, Science 285:1569-1572.
Rybakova et al. Utropin Binds Laterally along Actin Filaments and Can Couple Costameric Actin with Sarcolemma When Overexpressed in Dystrophin-deficient Muscle, May 2002, Molecular Biology of the Cell 13:1512-1521.
Sonnemannetal. Functional Substitution by TAT-Utrophin in Dystrophin-Deficient Mice, May 2009, PLoS Medicine 6(5):e1000083, pp. 1-10.
Amann et al. (1999). Utrophin lacks the rod domain actin binding activity of dystrophin.J. Biol. Chem.274:35375-35380.
Amann et al. (1998). A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction.J. Biol. Chem.273:28419-28423.
Barchi et al. (1979). Characteristics of saxitoxin binding to the sodium channel of sarcolemma isolated from rat skeletal muscle.J. Physiol.295:383-396.
Blake et al. (1996). Utrophin: A structural and functional comparison to dystrophin.Brain Pathol.6:37-47.
Deconinck et al. (1997a). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.Cell90:717-727.
Deconinck et al. (1997b). Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice.Nature Med.3:1216-1221.
Eddinger et al. (1986). Mechanical and histochemical characterization of skeletal muscles from senescent rats.Am. J. Physiol.251:C421-C430.
Ervasti et al. (1991). Purification of dystrophin from skeletal muscle.J. Biol. Chem.266:9161-9165.
Gregorevic et al. (2003). Gene therapy for muscular dystrophy—a review of promising progress.Expert. Opin. Biol. Ther.3:803-814.
Guo et al. (1996). Cloning and expression of full length mouse utrophin: The differential association of utrophin and dystrophin with AChR clusters.FEBS Lett.398:259-264.
Hoffman et al. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus.Cell51:919-928.
Ishikawa-Sakurai et al. (2004). ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan.Hum. Mol. Genet.13:693-702.
Kramarcy et al. (1994). Association of utrophin and multiple dystrophin short forms with the mammalianMr58,000 dystrophin-associated protein (syntrophin).J. Biol. Chem.269:2870-2876.
Kuppuswamy et al. (1989). Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.Nucleic Acids Research,17(9):3551-3561.
Lindsay, M.A. (2002). Peptide-mediated cell delivery: application in protein target validation.Curr. Opin. Pharmacol.2:587-594.
Marriott et al. (1988). Spectroscopic and functional characterization of an environmentally sensitive fluorescent actin conjugate.Biochemistry27:6214-6220.
Matsumura et al. (1992). Association of dystrophin-related protein with dystrophin-associated proteins inmdxmouse muscle.Nature360:588-591.
Miyata et al. (1997). Cooperative association of actin protomers and crosslinked actin oligomers in filaments at low ionic strength.J. Biochem.(Tokyo) 121:527-533.
Moens et al. (1993). Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch.J. Muscle Res. Cell Motil.14:446-451.
Petrof et al. (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction.Proc. Natl. Acad. Sci. U.S.A.90:3710-3714.
Rybakova et al. (1996). A new model for the interaction of dystrophin with F-actin.J. Cell Biol.135:661-672.
Rybakova et al. (1997). Dystrophin-glycoprotein complex is monomeric and stabilizes actin filaments in vitro through a lateral association.J. Biol. Chem.272:28771-28778.
Rybakova et al. (2006) Dystrophin and utrophin bind actin through distinct modes of contact.J. Biol Chem.281 (15): 9996-10001.
Snyder et al. (2004). Cell penetrating peptides in drug delivery.Pharm. Res.21:389-393.
Tinsley et al. (1998). Expression of full-length utrophin prevents muscular dystrophy inmdxmice.Nature Med.4:1441-1444.
Tinsley et al. (1992). Primary structure of dystrophin-related protein.Nature360:591-593.
Winder et al. (1995). Utrophin actin binding domain: analysis of actin binding and cellular targeting.J. Cell Sci.108:63-71.

Affiliated with

Also associated with

Rating

TAT-utrophin as a protein therapy for dystrophinopathies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TAT-utrophin as a protein therapy for dystrophinopathies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TAT-utrophin as a protein therapy for dystrophinopathies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2723111